The Application of Antibody Structure Modeling Strategies on Developing Antibody

Posted by Jerry Carter on August 26th, 2019


Ofloxacin is the 3rd generation quinolone antimicrobial agent which has a wide spectrum of antimicrobial activity, including a strong antimicrobial effect on Gram-positive bacteria and gram-negative bacteria, mycoplasma pneumoniae. It is widely used in animal husbandry production. However, the quinolones have some side effects on human body, like adverse reactions to gastrointestinal tract, adverse nervous system and cardiotoxicity. Residual toxicity in livestock can cause serious harm to the environment and human health. 

As the third generation of antibodies, single chain antibodies are designed, modified and reassembled by DNA recombination technology and protein engineering technology. In the appropriate expression vector, SCFs are expressed in the appropriate host cells and folded correctly into an antibody molecule with biological functions, revealing incomparable advantages in the Enzyme-linked immunosorbent assay (ELISA) test while detecting antibiotic residues in environment and food due to its low molecular weight, high plasticity and large-scale production without immunization of animals. 

To Conclude, developing a single change antibody targeting against ofloxacin is crucial.

For years’ devotion in the area of antibody development and engineering, Creative Biolabs is confident with assisting global clients with their pharmaceutical manufacturing projects and relative researches concerning about the antibody development.

Antibody Structure Modeling

Creative Biolabs offers advanced antibody structure modeling services, based upon the most up-to-date in silico technologies and the various strategies. There are two antibody modeling strategies adopted: homology modeling and antibody initio (or de novo) modeling.

1. Homology Antibody Modeling Service

The antibody homology modeling, one of the most commonly used methods, can help produce one or more targeted antibodies that posses similar structures.

This service is conducted in a systematic order.

1) Discover a template that is highly similar in the sequence to the unknown proteins with known structures.

2) Obtain the template structure and sequence alignment.

3) Generate homology models automatically to choose the best-qualified one.

4) Identify and refine the CDR loops with visual analysis and graphical tools.

All of the processes are done on the PreciAb™ platform.

2. Antibody de novo Modeling

Gaining attention and popularity recently, the de novo modeling stands as a promising star, which works primarily on the antibody complementarity-determining regions (CDRs) that can not be managed by the homology modeling. As for the CDR loops modeling, two methods are utilized, respectively loop grafting and de novo modeling.

1) Loop grafting: works well for CDR L1, L2, L3, H1 and H2 loops.

2) De novo modeling: predicts the antibody features not relying on the templates of loop regions.

Modeling of Antibody Framework Regions

Antibody molecule, made up of 4 polypeptides including 2 heavy chains and 2 light chains forming in the shape of “Y”, posses the variable region that is separated into 2 regions: hypervariable (HV) and framework (FR) regions (other names: complementarity-determining regions (CDRs).

Methods adopted by Creative Biolabs to build the models based upon templates;

1) Constructing a model based on a single Fv framework template.

2) Constructing a model by chimeric template.

3) Constructing a model five overall Fv framework templates.

Creative Biolabs’ services range not only covers modeling, but also comprehensive assessment to help clients be delivered the first level antibody models. Factors assessed include canonical structures, Carbonyl RMSD, VL/VH tilt angle, Cis-trans isomers, and CDR-H3, which will undergo check according to the 2 criteria, i.e. molprobity profile and rmsd values.

With Creative Biolabs’ comprehensive modeling services, obtaining the antibody 3D model is just a piece of cake. Due to the fact that the single chain antibodies reveal distinctive advantages on its small size, low immunogenicity and flexibility, it has gained attention in the medical area worldwide. Designing and engineering novel single chain antibodies (Ofloxacin Phage Antibody) with desired therapeutic properties will breakthrough the problems that hinder the pharmaceutical industry. For details accordingly, please visit


As a leading bio-tech company, Creative Biolabs bends efforts for antibody engineering in all fields, covering research, diagnosis, and therapy. Designing and engineering novel antibodies with desired therapeutic properties is now available based upon the comprehensive PreciAb™ platform, through customizing the service according to the specific requirements from the customers.

Like it? Share it!

Jerry Carter

About the Author

Jerry Carter
Joined: June 15th, 2019
Articles Posted: 52

More by this author